Drug pricing has emerged as one of the biggest issues for pharmaceutical companies this year, as the U.S. looks to dramatically reduce the costs paid by consumers.
As the largest single market for most pharma and biotech firms, higher drug prices in the U.S. — often nearly three times as costly as in other countries — are a key factor in the industry’s reliance on American sales, with branded drugs commanding even steeper premiums.
President Donald Trump has pushed for lower drug prices for Americans through so-called Most Favored Nations drug pricing, whereby the prices in the U.S. are set at the lowest price paid by other wealthy countries. That could have a tremendous impact on companies’ balance sheets.
But exactly how exposed are Europe’s biggest pharma companies to the U.S. market?
Among the 10 largest biopharmaceutical companies in the Stoxx 600 health index, five have a majority of their total sales from the U.S.: Roche
